BridgeBio Pharma (BBIO) Total Non-Current Liabilities (2018 - 2026)

BridgeBio Pharma's Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $3.6 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 44.43% year-over-year to $3.6 billion; the TTM figure through Mar 2026 stood at $3.6 billion (up 44.43% YoY), while the FY2025 annual figure was $3.0 billion, up 26.75% from the prior year.
• Total Non-Current Liabilities came in at $3.6 billion for Q1 2026 at BridgeBio Pharma, up from $3.0 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $3.6 billion in Q1 2026 to a low of $1.8 billion in Q1 2023.
• A 5-year average of $2.2 billion and a median of $1.9 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities slipped 0.81% in 2022 and surged 55.09% in 2025, its largest moves.
• BridgeBio Pharma's Total Non-Current Liabilities stood at $1.8 billion in 2022, then rose by 2.28% to $1.9 billion in 2023, then gained by 26.2% to $2.4 billion in 2024, then grew by 26.75% to $3.0 billion in 2025, then rose by 20.82% to $3.6 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $3.6 billion, $3.0 billion, and $2.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison